There are 3161 resources available
1276P - EXcellenT (exercise in extended oncogene addicted lung cancer in active treatment) trial: Preliminary results on impact of physical activity (PA) on emotional, metabolic and immune status
Presenter: Chiara Bennati
Session: Poster session 05
1277P - Optimising targeted therapy in NSCLC: A comprehensive analysis of oncogenic fusion mutations and co-mutation landscapes
Presenter: Li Dongge
Session: Poster session 05
1278P - Update of the INSPIRE study: Iruplinalkib versus crizotinib in ALK TKI-naïve locally advanced or metastatic ALK+ non-small cell lung cancer (NSCLC)
Presenter: Yuan-Kai Shi
Session: Poster session 05
1279P - First-line lorlatinib vs crizotinib in Asian patients with ALK+ non-small cell lung cancer (NSCLC): 5-year outcomes from the CROWN study
Presenter: Yi-Long Wu
Session: Poster session 05
1280P - Effects of semaglutide on the exposure of alectinib in patients with NSCLC
Presenter: Daan Lanser
Session: Poster session 05
1281P - Impact of common germline variants on the toxicity profile and pharmacokinetics of alectinib
Presenter: Niels Heersche
Session: Poster session 05
1282P - Activity of brigatinib based on genomic alterations detected on ctDNA at baseline and at progression in ALK inhibitor-naïve advanced ALK+ NSCLC from the ALTA-1L trial
Presenter: Laura Mezquita
Session: Poster session 05
1283P - Advanced ALK-positive non-small cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database
Presenter: Maria Lucia Reale
Session: Poster session 05
1284P - Clinical utility of liquid biopsy for non-small cell lung cancer patients with ALK fusion variants treated with brigatinib
Presenter: Lucía Robado de Lope
Session: Poster session 05
1285P - Deep learning prediction of response to advanced-generation ALK inhibitors (aALKi) in ALK-rearranged advanced NSCLC (aNSCLC) patients using digital pathology
Presenter: Amos Stemmer
Session: Poster session 05